Mounjaro injection dosage: how the schedule works from first pen to maintenance

Your first pen arrives and you are on 2.5 mg, here is what that actually means

Picture the scene: your Mounjaro pen is in the fridge door, next to the orange juice, and you are reading the leaflet wondering whether 2.5 mg is really doing anything. The honest answer is that 2.5 mg is not where the therapeutic weight-loss effect lives. It is there so that the nausea, reflux and stomach discomfort that can come with a GLP-1 or dual GIP/GLP-1 medicine hit you at the gentlest possible level. Mounjaro activates two gut-hormone receptors (GIP and GLP-1) which slow gastric emptying and reduce appetite. That mechanism is powerful, and ramping up slowly gives your gut time to adapt.

After four weeks at 2.5 mg, the standard next step under the licensed schedule is 5 mg. If you want to read more about what changes at that point, our page on Mounjaro 5 mg covers that dose in detail. The key thing to hold onto at this early stage is that feeling underwhelmed by the starter dose is completely normal, and that the pace of progression is a clinical decision, not something you should adjust yourself.

How the middle doses work, and what 'highest tolerated dose' means in practice

After 5 mg, the licensed schedule moves through 7.5 mg, 10 mg and 12.5 mg, each roughly four weeks apart. The phrase you will see in the clinical literature is "highest tolerated dose", meaning that if side effects at a given step are persistent and affecting your quality of life, your prescriber may recommend staying at the current strength rather than moving up. That is not a failure. Some people find 7.5 mg or 10 mg to be the point where appetite reduction is meaningful and tolerability is comfortable, and they stay there.

Side effects across the schedule are mostly gastrointestinal: nausea, loose stools, indigestion and burping are the most commonly reported, typically at their worst in the days after a dose increase and settling over the following one to two weeks. Severe or persistent abdominal pain that radiates to the back warrants prompt medical attention, the MHRA highlighted acute pancreatitis as an infrequent but serious possibility with GLP-1 medicines in a Drug Safety Update published in January 2026. That context belongs alongside any honest description of the titration journey.

For a broader look at how dose options compare across the full range, the Mounjaro injection doses overview sets them side by side.

Reaching 15 mg, and what the evidence says about higher doses

The 15 mg dose is the ceiling of the licensed schedule. SURMOUNT-1, a 72-week phase 3 trial involving thousands of adults, found that participants on 15 mg tirzepatide achieved an average body-weight reduction of around 20 to 21 percent. Those results were published in the New England Journal of Medicine and underpinned NICE's recommendation of tirzepatide for weight management in adults with a BMI of 35 or above plus at least one weight-related condition, with lower BMI thresholds applying for certain ethnic backgrounds under NICE technology appraisal TA1026.

Reaching 15 mg takes a minimum of around five months on the standard titration schedule. Some people get there sooner if earlier doses are very well tolerated; others take longer because their prescriber keeps them at an intermediate dose while a side effect resolves. The Mounjaro dosage for weight loss page goes deeper into how trial outcomes relate to the different dose levels if that is what you are trying to understand.

It is also worth knowing that some people explore whether the maintenance frequency can be adjusted. Our page on Mounjaro maintenance dosing every two weeks explains what the evidence says about extended intervals, though any such change is a prescriber-led decision, not something to try without clinical input.

Practical things that come up during the dosage schedule

A question our prescribers hear often is what to do if a dose is missed or if the pen has been left at room temperature for longer than expected. The short answer is the same each time: the Patient Information Leaflet that comes with your treatment and the guidance of your prescriber take precedence over anything you read on a website, including this one. Dosing decisions belong in that clinical relationship.

On the cost side, higher doses involve higher per-pen prices across the UK market, a practical consideration for anyone planning treatment over several months. The Mounjaro pricing page explains how private costs are structured and what a legitimate price should include. What it should always include, whatever the dose, is a prescription issued following a genuine clinical assessment, Mounjaro is not a medicine that can legally be supplied without one.

If you are trying to understand how tirzepatide's dosing compares to other GLP-1 medicines, the tirzepatide injection dosage overview places it in broader context. And if you are at the point of weighing up whether to start, the weight-loss treatments page explains how a consultation with our prescribers works. Check your eligibility there, a prescriber will review your details the same day, and the consultation is free.